MAPLE GROVE, Minn., Oct. 2, 2019 /PRNewswire/ -- Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the launch of Tosymra ™ (sumatriptan) Nasal Spray, 10 mg for the acute treatment of ...
Tosymra (sumatriptan) is a brand-name drug that’s prescribed to treat migraine with or without aura in adults. Tosymra comes as a nasal spray that’s used when needed to manage a migraine episode.
Sumatriptan 5mg, 20mg; per spray. The vascular 5-HT 1 receptor subtype to which sumatriptan binds selectively, and through which it presumably exerts its antimigrainous effect, is present on cranial ...
The FDA has approved sumatriptan nasal spray (Tosymra) for the acute treatment of migraine with or without aura in adults. The FDA has approved sumatriptan nasal spray (Tosymra) for the acute ...
Tosymra Nasal Spray 10 mg is a Proprietary Acute Migraine Treatment Approved Under the 505(b)2 Pathway Based on Bioequivalence to Imitrex (sumatriptan) Injection 4 mg GlaxoSmithKline Recently Notified ...
Lannett Company, Inc. (NYSE: LCI) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Sumatriptan Nasal ...
Objective: To study the efficacy and practicality of treating headache in professional footballers with intranasal sumatriptan. Results: Thirty eight attacks were analysed. The two hour response ...
Tosymra (sumatriptan) is a prescription drug used to treat migraine. The drug comes as a nasal spray. You usually use a single dose, which may be repeated two more times in a 24-hour period if needed.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback